Breaking News

LGC Acquires The Native Antigen Company

NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to support the global response to the COVID-19 pandemic.

By: Contract Pharma

Contract Pharma Staff

LGC has acquired The Native Antigen Company (NAC), a leading supplier of high quality infectious disease antigens and antibodies. NAC is a developer, manufacturer and supplier of critical reagents to the in vitro diagnostic (IVD), pharmaceutical and academic sectors. It offers a portfolio of native and recombinant infectious disease antigens and related products including pathogen receptors, virus-like particles and antibodies for use in immunoassay applications, vaccine development and qual...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters